For the quarter ending 2025-09-30, MRSN had -$20,581K decrease in cash & cash equivalents over the period. -$3,192K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -7,545 | -48,419 |
| Depreciation | 83 | 603 |
| Impairment loss on property and equipment | -25 | -563 |
| Net amortization of premiums and discounts on marketable securities | 0 | 140 |
| Stock-based compensation | 1,154 | 4,764 |
| Non-cash operating lease expense | 859 | 1,683 |
| Loss on extinguishment of debt | -378 | - |
| Other non-cash items | 3 | -154 |
| Accounts receivable | -98 | 266 |
| Prepaid expenses and other current assets | 525 | 142 |
| Other assets | 0 | 0 |
| Accounts payable | -530 | -1,407 |
| Accrued expenses | -370 | -3,781 |
| Operating lease liabilities | -976 | -1,878 |
| Other liabilities | 0 | -594 |
| Deferred revenue | 4,160 | -3,068 |
| Net cash used in operating activities | -3,192 | -51,928 |
| Maturities of marketable securities | 0 | 27,000 |
| Purchase of marketable securities | 0 | 0 |
| Proceeds from sale of property and equipment | 372 | 395 |
| Purchase of property and equipment | 0 | 0 |
| Net cash provided by (used in) investing activities | 372 | 27,395 |
| Net proceeds from at-the-market facilities | 0 | 0 |
| Proceeds from exercise of stock options | 0 | 0 |
| Proceeds from sales of common stock under espp | 0 | 29 |
| Repayment of debt | 17,729 | 6,250 |
| Payments under finance lease obligations | 32 | 24 |
| Net cash (used in) provided by financing activities | -17,761 | -6,245 |
| Decrease in cash, cash equivalents and restricted cash | -20,581 | -30,778 |
| Cash and cash equivalents at beginning of period | 108,228 | - |
| Cash and cash equivalents at end of period | 56,869 | - |
Mersana Therapeutics, Inc. (MRSN)
Mersana Therapeutics, Inc. (MRSN)